Unnecessary Endoscopies Could Be Avoided with Fecal Blood Test
By LabMedica International staff writers Posted on 14 Oct 2016 |

Image: The Quantum Blue rapid test allow for the immediate measurement of fecal calprotectin (Photo courtesy of Bühlmann Laboratories).
The majority of primary care patients referred for bowel endoscopy do not have significant colorectal disease (SCD), and are unnecessarily exposed to a small but realistic risk of severe endoscopy-associated complications.
Serious colorectal diseases, including colorectal cancer, are difficult to diagnose as the signs and symptoms are not always clear. Any suspicion of SCD requires a general practitioner referral to a hospital for an endoscopy but studies have shown that between 60% to 80% of referred patients end up not having SCD.
Scientists at the University Medical Center Utrecht (Netherlands) collected data from the large-scale study where 810 patients suspected of SCD were enrolled from 266 primary care practices in the Netherlands. A pre-endoscopy venous blood sample was drawn to estimate hemoglobin and C-reactive protein (CRP) concentrations according to routine clinical practice. The team developed a diagnostic strategy to better exclude SCD in these patients and evaluated the value of adding a fecal calprotectin point-of-care (POC) and/or a POC fecal immunochemical test for hemoglobin (FIT-Hb)) to routine clinical information.
The investigators analyzed the fecal samples for calprotectin concentration by a quantitative point-of-care (POC) test (Quantum Blue; dynamic range 30 to 300 μg/g) and by an enzyme-linked immunosorbent assay (ELISA; EK-CAL Calprotectin ELISA, (both from Bühlmann Laboratories, Schönenbuch, Switzerland), both yielding estimates of μg calprotectin/g feces. For fecal Hb the team used a qualitative POC FIT, the Clearview iFOBT One Step Fecal Occult Blood Test Device, (Alere Health; Waltham, MA, USA), yielding either a positive or negative test result with a lower detection limit of 6 μg/g.
Out of the 810 patients referred for an endoscopy, 669 were found to have no SCD. Once the results of the FIT test had been taken into account the scientists found that approximately 30% of these patients could have been prevented from having an endoscopy as they may have been correctly diagnosed as not having SCD during their doctor’s visit. The study also looked at the benefit of adding a fecal test for the protein calprotectin to the diagnostic strategy. They found that this test also improved the diagnosis of SCD but not to the same extent as FIT. Furthermore, combining both tests added little extra benefit to the diagnostic accuracy of FIT alone.
The authors concluded that FIT and to a much lesser extent calprotectin POC testing showed incremental value for SCD diagnosis beyond standard clinical information. A diagnostic strategy with routine clinical data and a POC FIT test may safely rule out SCD and prevent unnecessary endoscopy referral in approximately one third of SCD-suspected primary care patients. The study was published on September 26, 2016, in the journal BMC Medicine.
Related Links:
University Medical Center Utrecht
Bühlmann Laboratories
Alere Health
Serious colorectal diseases, including colorectal cancer, are difficult to diagnose as the signs and symptoms are not always clear. Any suspicion of SCD requires a general practitioner referral to a hospital for an endoscopy but studies have shown that between 60% to 80% of referred patients end up not having SCD.
Scientists at the University Medical Center Utrecht (Netherlands) collected data from the large-scale study where 810 patients suspected of SCD were enrolled from 266 primary care practices in the Netherlands. A pre-endoscopy venous blood sample was drawn to estimate hemoglobin and C-reactive protein (CRP) concentrations according to routine clinical practice. The team developed a diagnostic strategy to better exclude SCD in these patients and evaluated the value of adding a fecal calprotectin point-of-care (POC) and/or a POC fecal immunochemical test for hemoglobin (FIT-Hb)) to routine clinical information.
The investigators analyzed the fecal samples for calprotectin concentration by a quantitative point-of-care (POC) test (Quantum Blue; dynamic range 30 to 300 μg/g) and by an enzyme-linked immunosorbent assay (ELISA; EK-CAL Calprotectin ELISA, (both from Bühlmann Laboratories, Schönenbuch, Switzerland), both yielding estimates of μg calprotectin/g feces. For fecal Hb the team used a qualitative POC FIT, the Clearview iFOBT One Step Fecal Occult Blood Test Device, (Alere Health; Waltham, MA, USA), yielding either a positive or negative test result with a lower detection limit of 6 μg/g.
Out of the 810 patients referred for an endoscopy, 669 were found to have no SCD. Once the results of the FIT test had been taken into account the scientists found that approximately 30% of these patients could have been prevented from having an endoscopy as they may have been correctly diagnosed as not having SCD during their doctor’s visit. The study also looked at the benefit of adding a fecal test for the protein calprotectin to the diagnostic strategy. They found that this test also improved the diagnosis of SCD but not to the same extent as FIT. Furthermore, combining both tests added little extra benefit to the diagnostic accuracy of FIT alone.
The authors concluded that FIT and to a much lesser extent calprotectin POC testing showed incremental value for SCD diagnosis beyond standard clinical information. A diagnostic strategy with routine clinical data and a POC FIT test may safely rule out SCD and prevent unnecessary endoscopy referral in approximately one third of SCD-suspected primary care patients. The study was published on September 26, 2016, in the journal BMC Medicine.
Related Links:
University Medical Center Utrecht
Bühlmann Laboratories
Alere Health
Latest Pathology News
- AI Tool Accurately Determines Breast Cancer Prognosis
- Powerful New Tool Improves Tissue Cancer Analysis
- AI-Based Tool Measures Cancer Aggressiveness
- Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels
- New AI-Based Method Effectively Identifies Disease Phenotypes Using Light-Based Imaging
- AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care
- AI Tool Enhances Interpretation of Tissue Samples by Pathologists
- AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
- Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
- New Lab Model to Help Find Treatments for Aggressive Blood Cancer
- AI-Supported Microscopy Improves Detection of Intestinal Parasite Infections
- AI Performs Virtual Tissue Staining at Super-Resolution
- AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis
- Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
- Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
- Saliva-Based Testing to Enable Early Detection of Cancer, Heart Disease or Parkinson’s
Channels
Molecular Diagnostics
view channel
Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis
Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more
New Gene Tool to Enable Earlier Detection and Treatment of Cardiometabolic Diseases
Cardiometabolic diseases, which affect the heart, blood vessels, and the body's ability to process food and generate energy, are difficult to diagnose early due to the complex genetic changes that contribute... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy
To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more
Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer
Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more
Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes
Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read moreMicrobiology
view channel
Early Detection of Gut Microbiota Metabolite Linked to Atherosclerosis Could Revolutionize Diagnosis
Cardiovascular disease is the leading cause of death worldwide, and atherosclerosis plays a critical role in its development. This chronic condition, characterized by the hardening and narrowing of arteries... Read more
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Tool Accurately Determines Breast Cancer Prognosis
A new study has found that cells and tissues surrounding a breast cancer tumor may hold critical information about how patients will respond to treatment. The research, published in the journal Patterns,... Read more
Powerful New Tool Improves Tissue Cancer Analysis
Studying the mix of cell types in human tissue is crucial for understanding diseases like cancer, but it presents significant challenges in both accuracy and scalability. The tumor microenvironment, composed... Read moreTechnology
view channel
Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells
A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Safer, Portable and Low-Cost Imaging Solution to Revolutionize Biomedical Diagnostics
In diagnosing diseases and monitoring treatment, accurate and quick detection of temperature within biological tissues can be crucial, especially in early disease detection. Conventional methods such as... Read more
Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation
Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read moreIndustry
view channel
QuidelOrtho and BÜHLMANN Collaborate on Gastrointestinal Biomarker Tests
QuidelOrtho Corporation (San Diego, CA, USA) and BÜHLMANN Laboratories AG (Schönenbuch, Switzerland) have announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's... Read more